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TP53 missense mutations leading to the expression of mutant p53 oncoproteins are frequent
driver events during tumorigenesis. p53 mutants promote tumor growth, metastasis and
chemoresistance by affecting fundamental cellular pathways and functions. Here, we
demonstrate that p53 mutants modify structure and function of the Golgi apparatus, cul-
minating in the increased release of a pro-malignant secretome by tumor cells and primary
fibroblasts from patients with Li-Fraumeni cancer predisposition syndrome. Mechanistically,
interacting with the hypoxia responsive factor HIF1α, mutant p53 induces the expression of
miR-30d, which in turn causes tubulo-vesiculation of the Golgi apparatus, leading to
enhanced vesicular trafficking and secretion. The mut-p53/HIF1α/miR-30d axis potentiates
the release of soluble factors and the deposition and remodeling of the ECM, affecting
mechano-signaling and stromal cells activation within the tumor microenvironment, thereby
enhancing tumor growth and metastatic colonization.
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The crosstalk of cancer cells with the tumor microenviron-ment (TME) plays a crucial role in tumor growth andprogression. Tumors reprogram their secretory phenotype
to shape a permissive microenvironment, supporting local inva-
sion and colonization of metastatic niches1. This involves the
release of soluble factors stimulating angiogenesis and recruiting
stromal and immune cell populations2,3, as well as deposition and
remodeling of the extra-cellular matrix (ECM) to sustain
mechano-stimulation4.
While many molecules and cell types involved in
tumor–stroma communication have been characterized, factors
responsible for reprogramming the secretory activity of tumor
cells remain poorly understood. Several reports indicate that
cancer cells adapt their secretory machinery, namely the endo-
plasmic reticulum (ER) and the Golgi apparatus (GA), to face
increased protein translation and secretion5,6. Moreover, recent
evidence suggests that alterations of the GA and optimization of
vesicular trafficking endow cancer cells with aggressive and
metastatic phenotypes7,8. How these alterations relate to onco-
genic signaling is, however, largely unknown.
Missense mutations in the TP53 gene, causing expression of
mutant p53 proteins (mut-p53), are among most frequent genetic
alterations in human cancers, and are associated with the Li-
Fraumeni syndrome, a rare familial cancer predisposition9,10.
Mut-p53 loses tumor suppressive functions and can acquire
properties that enable it to rewire the cell’s transcriptome and
proteome, promoting tumor growth, chemoresistance, and
metastasis11–13. Mut-p53 becomes frequently stabilized and
activated by mechanical cues such as ECM stiffness14, and
impacts on the crosstalk between cancer cells and stroma by
regulating the expression of cytokines and chemokines, thereby
inducing tumor cell migration and invasion in a paracrine fash-
ion15. However, the impact of mut-p53 on the secretory
machinery and the effects of mut-p53-dependent secretome on
TME at local and distal sites remain poorly defined. p53 missense
mutants have been shown to regulate several miRNAs16,17, some
of which are secreted and concur to malignant evolution by long-
range effects18.
In this work we investigate how mut-p53 modifies cellular
processes altering the communication of cancer cells with their
microenvironment. As potential mediators of this activity we
focused on mut-p53 regulated miRNAs, a class of molecules
capable of modulating at multiple levels entire cellular processes.
We discovered that mut-p53, through its target miR-30d, controls
secretory trafficking in cancer cells by causing tubulo-vesiculation
of the GA. This increases the release of a pro-malignant secre-
tome, which impacts on TME, fostering tumor growth, and
metastatic colonization.
Results
MicroRNA-30d is a novel target of mutant p53. To identify
mut-p53 target miRNAs, we silenced mut-p53R280K in MDA-MB-
231 breast cancer cells by RNAi and monitored the levels of a panel
of miRNAs, previously found overexpressed in solid tumor types at
high frequency of missense TP53 mutations19,20 (Supplementary
Fig. 1a). Among miRNAs whose expression was reduced upon mut-
p53 knockdown we identified miR-30d, previously reported to exert
oncogenic activities21–25. miR-30d expression was significantly
reduced upon mut-p53 knockdown, while re-introduction of
siRNA-insensitive p53R280K increased it (Fig. 1a). Similar effects
were observed in cell lines harboring different mut-p53 variants,
from breast (MD-MB-468/p53R273H, SK-BR-3/p53R175H, and
SUM-159PT/p53R158insS) (Fig. 1b), prostate, colon, liver, and
ovarian cancer (DU 145/p53P223L,V274F, HT-29/p53R273H, Mah-
lavu/p53R249S, TOV-112D/p53R175H, Supplementary Fig. 1b).
Silencing wild-type p53 had no effect on miR-30d levels in HBL100
and MCF-7 cancer cells, as well as in MCF10A normal-like breast
epithelial cells (Fig. 1c, Supplementary Fig. 1c). Conversely, ectopic
expression of mut-p53 variants R175H, R273H and R280K in
MCF10A cells, stably silenced for wt-p53, increased miR-30d
expression (Fig. 1c). Confirming dependence on mut-p53, miR-30d
levels were reduced upon treating MDA-MB-231 cells with the
mut-p53 inactivating agent APR-246/PRIMA-1MET, able to restore
wt-p53 function26 (Supplementary Fig. 1d). Moreover, uncoupling
mechanosignaling by culturing cells on soft matrix, or by treatment
with the myosin II inhibitor Blebbistatin or the HDAC6 inhibitor
sulforaphane significantly reduced mut-p53 levels and miR-30d
expression, similar to mut-p53 silencing (Supplementary Fig. 1d, e).
Mut-p53 induces miR-30d expression through HIF1α. We next
investigated the mechanism of miR-30d regulation by mut-p53.
qPCR analysis indicated that mut-p53 modulates the levels of
primary (pri-miR-30d), precursor (pre-miR-30d), and mature
miR-30d to similar extent (Fig. 1a, d), suggesting that it controls
miR-30d transcription. The genomic regulatory regions of
MIR30D are uncharacterized, however, the region surrounding
the transcription start site27,28 displayed active promoter chro-
matin marks29 (Supplementary Fig. 1f), was identified as a target
of mut-p53 by ChIP-sequencing30, and is bound by Hypoxia-
Induced Factors HIF1α and HIF2α under hypoxia31. This
prompted us to test whether mut-p53 could regulate miR-30d
transcription through HIFs. As shown in Supplementary Fig. 1g,
ectopic expression of HIF1α increased miR-30d levels, while its
depletion downregulated both precursor and mature miR-30d in
MDA-MB-231 cells (Supplementary Fig. 1h). In addition, silen-
cing either HIF1α or mut-p53 prevented the induction of miR-
30d by hypoxia (2% pO2) (Fig. 1e). Since mut-p53 transcriptional
activity changes upon shifting cells from 2D to 3D culture32, we
confirmed that miR-30d induction by hypoxia was dependent on
mut-p53 also when culturing MDA-MB-231 cells in 3D (Sup-
plementary Fig. 1i).
Next, we verified whether mut-p53 and HIF1α interact:
proximity ligation assays (PLA) revealed nuclear complexes
between mut-p53 and HIF1α, whose formation was enhanced
under low oxygen pressure as well as upon hypoxia-mimetic
treatment with CoCl2 (Fig. 1f). Similar results were obtained by
co-immunoprecipitation of mut-p53 and HIF1α proteins from
lysates of MDA-MB-231 cells grown under different oxygen
pressure (Supplementary Fig. 1j), as well as from MDA-MB-468
cells, both in normoxia and upon hypoxia-mimetic treatment
(Supplementary Fig. 1k).
Consistently, analysis of a breast cancer gene expression
dataset33 highlighted a correlation between TP53 missense
mutations and high HIF1α activity (Supplementary Fig. 1l).
Moreover, high miR-30d expression was associated with TP53
mutation and with high HIF1α levels in cancer gene expression
datasets (Supplementary Fig. 1m, n).
Finally, to verify whether mut-p53 and HIF1α cooperatively
activate the MIR30D promoter, we performed ChIP experiments in
MDA-MB-231 cells. Under normoxia we observed binding of mut-
p53 toMIR30D promoter, that was further enhanced under hypoxia
in a HIF1α-dependent manner (Fig. 1g). On the other hand, mut-
p53 was required for efficient recruitment of HIF1α to MIR30D
promoter under normoxia and hypoxia (Fig. 1h), and for histone
H3 Lysine 9 acetylation (H3K9ac) (Fig. 1i), which occurs during
hypoxia-induced transcriptional activation34 at this genomic region.
These results suggest that in cancer cells, mut-p53 and HIF1α
form an active transcriptional complex on MIR30D promoter,
leading to miR-30d expression already in normoxic conditions,
further increased by hypoxia.
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Fig. 1 Mutant p53 induces miR-30d expression through HIF1α. a miR-30d expression was evaluated by RT-qPCR, normalized to U6B RNA expression
levels, in MDA-MB-231 cells upon silencing endogenous mut-p53 with a siRNA targeting the 3′UTR (sip53u); expression of mut-p53 R280K was rescued
by transfecting a siRNA-resistant mut-p53 HA-R280K construct. Bottom: western blot analysis of p53 expression using HSP90 as loading control.
b Expression levels of miR-30d were analyzed as in (a) upon silencing of mut-p53 in the indicated human breast cancer cell lines. c Endogenous wt-p53
was stably silenced in MCF10A mammary epithelial cells (shp53), and shRNA-resistant forms of the indicated p53 mutants were expressed by viral
transduction where indicated. miR-30d expression was then evaluated as in (a). d mut-p53 was silenced in MDA-MB-231 cells as in (a); expression of pri-
miR-30d and pre-miR-30d was then evaluated by RT-qPCR, normalized, respectively, to the expression of H3 and U6B RNA. e Expression of miR-30d was
evaluated by RT-qPCR as in (a), upon silencing of either mut-p53 or HIF1α in MDA-MB-231 cells cultured either in normoxic (20% pO2) or hypoxic
conditions (2% pO2) for 16 h. Right: western blot analysis of HIF1α and mut-p53 levels, using actin as a loading control. f Proximity ligation assay (PLA)
with primary antibodies against p53 and HIF1α were performed in MDA-MB-231 cells cultured either under normoxic (20% pO2) or hypoxic conditions
(2% pO2) for 16 h, or exposed for 16 h to 150 μM CoCl2 as hypoxia-mimetic treatment. g–i Lysates of MDA-MB-231 cells cultured under the indicated
conditions for 16 h upon silencing of either mut-p53 or HIF1α were subjected to chromatin immunoprecipitation (ChIP) analysis with anti-p53 FL-393 (g),
HIF1α (h), and Acetyl-Histone H3 (Lys9) antibodies (i), or Protein A/G PLUS-Agarose as negative control. Binding to MIR30D promoter region was
calculated as fraction of input chromatin bound. Binding to non-specific chromatin is shown in Supplementary Fig. 1o-p-q. Graphs represent the individual
data points, the mean+/− SEM of three independent experiments. Blots are representative of n= 3 biological replicates. P value (*p < 0.05, **p < 0.01,
***p < 0.001) was calculated by two-tailed unpaired Student’s t-test.
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miR-30d regulates genes involved in the secretory pathway. At
first, we analyzed the impact of the mut-p53/miR-30d axis on cell
transformation in vitro. Consistently with previous reports32,35,
MCF10A cells exhibited normal acinar morphogenesis in 3D
cultures, while ectopic expression of mut-p53 variants R175H or
R280K, but not wt-p53 silencing per se36, inhibited luminal
clearance, reminiscent of the filled lumen phenotype of ductal
carcinoma in situ (Supplementary Fig. 2a). In this context, inhi-
bition of miR-30d by a decoy vector (dy-30d)37 abolished luminal
filling (Supplementary Fig. 2a), suggesting that miR-30d mediates
oncogenic phenotypes downstream to mut-p53.
To identify cellular processes regulated by miR-30d, we
performed gene expression analysis in MDA-MB-231 cells stably
transduced with dy-30d (hereafter referred to as MDA-MB-231/
dy-30d). Functional annotation analysis revealed that differen-
tially expressed genes mainly belong to functional categories of
protein transport, vesicular trafficking and Golgi organization
(Fig. 2a; Supplementary Data File 1). Gene Set Enrichment
Analysis (GSEA) indicated that genes regulated by miR-30d are
involved in protein secretion (Fig. 2b). We validated a panel of
these targets by qRT-PCR upon miR-30d overexpression in
MDA-MB-231 cells. As shown in Supplementary Fig. 3b, miR-
30d enhanced the expression of key components of ER-related
transport (e.g., SEC11C, SSR1) and of ER-Golgi vesicular
trafficking machinery (e.g., SEC23A, SEC24A, SEC24B, COPB1,
ARF4, ARFGEF1, GOSR2), while reducing the expression of
negative regulators of ER-Golgi trafficking (e.g., ARFGAP2) and
kinesin-mediated retrograde transport (e.g., KIF20A). In sum,
gene expression data suggest that miR-30d could modulate
secretory trafficking.
We then asked if miR-30d affects protein secretion. MDA-MB-
231/dy-30d and control cells were metabolically labeled with
S35Met/Cys aminoacids, and proteins secreted in the conditioned
medium (CM) were analyzed by SDS-PAGE and autoradiography.
As shown in Fig. 2c, miR-30d depletion significantly decreased total
protein secretion. This was not due to reduced protein synthesis, as
levels of intracellular proteins were not appreciably affected
(Supplementary Fig. 3c). mut-p53 knockdown similarly reduced
secretion, that was rescued by concomitant miR-30d overexpression
(Fig. 2d, Supplementary Fig. 3d).
These results were recapitulated in mut-p53R273H expressing
MDA-MB-468 cells (Supplementary Fig. 3e), and in isogenic
MCF10A-derived cells expressing either mut-p53R175H or mut-
p53R280K (Supplementary Fig. 3f), indicating that different p53
mutants share the ability to control secretory trafficking, while
knockdown of wt-p53 did not significantly affect protein
secretion (Supplementary Fig. 3f). Finally, we verified that HIF1α
knockdown dampened protein secretion, while HIF1α stabiliza-
tion by CoCl2 promoted it (Supplementary Fig. 3g), in line with
the observation that HIF1α upregulates miR-30d.
We then sought to confirm these results using a reporter for
canonical protein secretion38 (ssGFP), that localizes along the
whole secretory pathway (Supplementary Fig. 4a). In line with
above results, mut-p53 knockdown reduced the amount of
secreted ssGFP in MDA-MB-231 cells, while miR-30d over-
expression reversed the effect both in 2D and 3D cultures (Fig. 2e
and Supplementary Fig. 4b). Similar results were obtained in DU
145 (mut-p53P223L, V274F), HT-29 (mut-p53R273H), and Mahlavu
(mut-p53R249S) cells (Supplementary Fig. 4c–e). Similarly, ssGFP
secretion was dampened upon mut-p53 inactivation with APR-
246/PRIMA-1MET, or by reducing mut-p53 stability interfering
with mechanosignaling (Supplementary Fig. 4f). As shown in
Fig. 2f, inhibition of miR-30d with dy-30d strongly reduced the
ability of mut-p53R280K to enhance ssGFP secretion in MCF10A
cells. Finally, silencing mut-p53 in MDA-MB-231 cells transfected
with a miR-30d-inhibitor hairpin (IH-30d) did not lead to
significant further reduction of ssGFP secretion (Supplementary
Fig. 4g), confirming that in these conditions miR-30d is a major
mediator of the effect of mut-p53 on secretion.
Consistently with the observed induction of miR-30d by
HIF1α, knockdown of HIF1α dampened ssGFP secretion,
whereas hypoxia promoted it in a miR-30d-dependent manner
(Fig. 2g).
Altogether, these results suggest that the mut-p53/HIF1α/miR-
30d axis stimulates protein secretion in cancer cells.
The mut-p53/miR-30d axis impacts cell secretory machinery.
To characterize the proteins whose secretion is stimulated by
mut-p53/miR-30d, we performed mass spectrometry analysis by
LC–MS/MS technology on CMs collected from control and mut-
p53-KD MDA-MB-231 cells, and from same cells overexpressing
miR-30d (details in Supplementary Fig. 4h and Methods).
As shown in Fig. 2h, mut-p53 knockdown altered significantly
the protein secretome of MDA-MB-231 cells, with both up- and
downregulation of a large number of hits; notably, overexpressing
miR-30d largely reverted the effects of mut-p53 knockdown.
We then compared mut-p53 secretome data with mut-p53-
dependent transcriptome and proteome data previously obtained
in the same cell line30. This revealed that only about 30% (247/
815) of differentially secreted proteins were regulated also at the
transcript or protein level upon mut-p53 knockdown (Fig. 2i),
with a striking discrepancy between miR-30d-dependent secre-
tome and transcriptome (only 11% hits in common, 107/988)
(Fig. 2j). This indicates that the effect of mut-p53/miR-30d on
protein secretion depends only in part on altered expression of
secreted proteins, implying that it could impinge on the secretion
process.
Hence, we analyzed the secretory and trafficking pathway in
MCF10A cells, upon silencing wt-p53 and overexpressing either
mut-p53R280K or miR-30d, by monitoring marker expression and
organelle morphology relative to ER, GA, COPI-II transport
vesicles, and microtubules. Levels of PDIA5, Sec24A, and GM130
proteins (markers for ER, COPI, and cis-Golgi compartments,
respectively) were increased upon mut-p53R280K and miR-30d
overexpression, while silencing wt-p53 did not affect them
(Supplementary Fig. 5a). Immunofluorescence and confocal
microscopy revealed that, while wt-p53 depletion did not alter the
structure of any component of the secretory pathway, expression of
either mut-p53R280K or miR-30d (Fig. 3a) caused strong alterations
of GA morphology, with only mild effects on ER morphology
(PDIA5), COP vesicles (Sec24A and β-COP), and microtubules (α-
tubulin). In more than 60% of miR-30d overexpressing cells, the
GA perinuclear ribbon-like structure was replaced by multiple
mini-stacks dispersed within the cytoplasm (Fig. 3a and Supple-
mentary Fig. 5b), a morphology hereafter defined as vesiculation.
This phenotype was confirmed by staining for HPA (a lectin that
binds glycans processed in cis-Golgi cisternae), Giantin (an
intercisternal cross-bridges marker), and TGN46 (a trans-Golgi
marker) (Supplementary Fig. 5c). Consistently, 3D image recon-
stitution using confocal Z-stacks revealed an increase from about 10
to 60 cis-Golgi elements per cell upon miR-30d overexpression
(Supplementary Fig. 5d and Movie 1).
Of note, GA alteration induced by mut-p53 in MCF10A cells
was reverted upon miR-30d inhibition by dy-30d (Fig. 3b).
Similarly, ectopic expression of mut-p53 variants R175H, R273H,
and R280K in p53-null H1299 lung cancer cells induced GA
vesiculation that was abrogated by inhibiting miR-30d (Supple-
mentary Fig. 5e). Moreover, MDA-MB-231 and Mahlavu cells
displayed a vesiculated GA morphology that was normalized
upon knockdown of mut-p53 or treatment with PRIMA-1MET,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17596-5


















Walerych et al. 2016
Proteome









0 1 2 3 4
Induced by hypoxia
Notch signaling involved in heart development
Antigen processing and presentation via MHC class I
Negative regulation of translation
ER-associated ubiquitin-dependent protein catabolic process
Golgi organization
Retrograde vesicle-mediated transport Golgi to ER
IRE1-mediated unfolded protein response
Response to endoplasmic reticulum stress
COPII vesicle coating




 Ubiquitin-dependent protein catabolic process
Cellular response to DNA damage stimulus











































Normalized enrichment score –1.5941
Enrichment plot: HALLMARK_PROTEIN_SECRETION
FDR qValue 0.012022106














0 5000 10,000 15,000 20,000
Rank in ordered dataset





























































































































































































































































    + B
FAsip53
    +







Fig. 2 mut-p53 and miR-30d regulate protein secretion. a Gene Ontology (GO) enrichment analysis of genes differentially expressed in MDA-MB-231
cells transduced with miR-30d decoy compared with control, using DAVID database. All terms were significant (p < 0.05) following Benjamini–Hochberg
correction. b Gene set enrichment analysis (GSEA) of hallmarks PROTEIN_SECRETION in MDA-MB-231-dy-30d transcriptome compared with control
(n= 3). c Analysis of protein secretion in MDA-MB-231-dy-30d cells by [35S]-methionine/cysteine labeling, SDS-PAGE, and autoradiography (top). The
inhibitor of ER-GA protein transport Brefeldin A (BFA, 2.5 μM) was used as control. Intracellular proteins are shown in Supplementary Fig. 3c. Right: ratio of
secreted vs intracellular labeled proteins quantified by densitometry. d Protein secretion analysis in MDA-MB-231 cells transfected with mut-p53 siRNA,
miR-30d mimic or combination, performed as in (c) (intracellular proteins are in Supplementary Fig. 3d). e MDA-MB-231 cells were transduced with
construct encoding secretion signal-fused GFP (ssGFP). Forty-eight hours upon silencing mut-p53, overexpressing miR-30d mimic or combination, fresh
medium was added and collected after 2 h. Bottom: ratio of secreted versus intracellular ssGFP quantified by densitometry. f Intracellular and medium
(CM) ssGFP levels were analyzed as in (e) in MCF10A cells silenced for wt-p53 (shp53) and overexpressing mut-p53R280K, and transduced with dy-30d or
control. g Intracellular and CM ssGFP levels were analyzed as in (e) in MDA-MB-231 cells upon silencing HIF1α or culturing in hypoxia (2% pO2) for 16 h,
and treated or not with miR-30d inhibitor. hMDA-MB-231 cells were transfected as in (d), and CM was analyzed by LC–MS/MS. Heatmap shows proteins
whose secretion was significantly altered. i Venn diagram showing overlap between proteins differentially secreted (h: secretome) upon mut-p53 silencing
in MDA-MB-231 cells and genes differentially expressed at protein (proteome) or RNA level (transcriptome) as reported in ref. 30. j Venn diagram showing
overlap between differentially secreted proteins (secretome) and differentially expressed transcripts (transcriptome) upon inhibiting miR-30d in MDA-
MB-231 cells by decoy construct (dy-30d). Graphs represent the individual data points, the mean+/− SEM of three independent experiments. Blots are
representative of n= 3 biological replicates. P value (*p < 0.05, **p < 0.01, ***p < 0.001) was calculated by two-tailed unpaired Student’s t-test. Source data
are provided as Source data file.
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and reverted by introduction of miR-30d (Fig. 3c and
Supplementary Fig. 5f).
These results confirm that mut-p53 modifies GA morphology
and miR-30d is a major mediator of this activity. Consistently
with the observed regulation of miR-30d by HIF1α, activation of
HIF1α by hypoxia or treatment with CoCl2 caused a similar
modification of GA structure that was reduced by miR-30d
inhibition (Supplementary Fig. 5g).
To characterize GA alterations induced by the mut-p53/miR-
30d axis, we performed ultrastructural analysis by correlative light
electron microscopy (CLEM) in MCF10A cells. While control
cells exhibited the canonical GA ultrastructure, miR-30d over-
expressing cells displayed tubulo-vesiculated GA, characterized by
narrow cisternae with large pores, intercisternal connections,
membrane invaginations, and swelling of cisternae (Fig. 3d). An
increased number of COPI vesicles was also detected. CLEM
analysis indicated that depletion of wt-p53 did not alter GA
structure, while mut-p53R280K overexpression caused appearance
of partially tubulated cisternae (Fig. 3d). Of note, miR-30d
inhibition restored the normal structure of GA stacks in mut-p53
overexpressing cells (Fig. 3d), confirming epistatic relationship.
Single cisternae reconstitution is shown in Supplementary
Fig. 5h-l.
Alterations of GA structure similar to those induced by mut-p53/
miR-30d have been previously reported to accelerate diffusion of
soluble proteins from cis- to trans-Golgi, leaving unaffected or
reducing the trafficking of non-diffusible cargoes including











































































































































































































Fig. 3 The mut-p53/miR-30d axis modifies the cell secretory machinery. a Immunofluorescence analysis of PDIA5 (ER), SEC24 (COPII), βCOP (COPI),
GM130 (cis-Golgi), and α-tubulin (microtubules) in MCF10A cells, upon stable silencing of endogenous wild-type p53 (shp53) either alone or combined
with overexpression of mut-p53 R280K or miR-30d mimic. Nuclei were stained with Hoechst. Scale bar, 20 µm. b Immunofluorescence analysis of Golgi
apparatus stained with an antibody specific for GM130 in MCF10A cells stably silenced for endogenous p53 (shp53) and overexpressing mut-p53 R175H,
R273H, or R280K forms, and transduced either with control or miR-30d decoy construct. Scale bar, 20 µm. Right: graph showing the percentage of cells
with vesiculated Golgi upon different treatments. c Immunofluorescence analysis of Golgi apparatus stained with an antibody specific for GM130 in MDA-
MB-231 cells upon silencing of mut-p53, overexpression of a miR-30d mimic, their combination or treatment for 24 h with 10 µM PRIMA-1 as indicated.
Scale bar, 20 µm. Right: graph showing the percentage of cells with vesiculated Golgi upon different conditions. d Top: confocal superresolution microscopy
analysis of Golgi structure in MCF10A cells subjected to the indicated treatments, and stained for GM130 antigen. Middle: electron tomography of the
above samples. Bottom: three-dimensional model of the Golgi stacks highlighted in the middle panels, showing the Golgi cisternae. Arrowheads indicate
vesicular-tubular clusters in cells overexpressing miR-30d or mut-p53 R280K. e Images show the cellular localization of the RUSH reporter MannII-SBP-
EGFP at the indicated time points after addition of biotin in MCF10A cells transfected with either CTRL or miR-30d mimic. Scale bar, 20 µm. Bottom: plots
show total fluorescence intensity in the Golgi region at each time point, corrected for background and normalized to the fluorescence before release.
Curves depict the measurement of 20 cells for each condition. Time per condition p value <0.0001 was calculated by two-way ANOVA test. In (b–d)
graphs represent the individual data points and the mean+/− SEM of three independent experiments. P value (*p < 0.05, **p < 0.01, ***p < 0.001) was
calculated by two-tailed unpaired Student’s t-test). Micrographs are representative of n= 3 biological replicates. Source data are provided as Source
data file.
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vesicles suggests that enhanced retrieval of ER and Golgi resident
proteins may occur to maintain the correct intracisternae
distribution of Golgi enzymes. To analyze alterations of protein
transport kinetics induced by mut-p53/miR-30d we employed the
RUSH reporter system, which allows to synchronize ER exit of
ectopically expressed proteins41. We transfected as reporter the α-
mannosidase II (MannII) fused to streptavidin binding domain
together with a Streptavidin-KDEL construct as a hook for ER
retention. MannII allows to follow the traffic from ER to medial-
trans-Golgi42,43. As shown in Fig. 3e, miR-30d overexpression
associated with faster Golgi localization of MannII (20min upon
synchronization vs 50min in control cells).
These results demonstrate that mut-p53, via miR-30d, modifies
the secretory machinery by inducing tubulo-vesiculation of the
Golgi apparatus and increases trafficking rate.
miR-30d regulates targets involved in the secretory pathway.
We sought to identify candidate miR-30d targets that could
mediate the observed phenotypes. Having shown that miR-30d
expression is induced by mut-p53 and HIF1α, we used available
transcriptomic data to compare three gene lists: (i) genes down-
regulated by mut-p53 (sip53 UP, i.e., genes upregulated by mut-
p53 KD in MDA-MB-231 cells30, (ii) genes downregulated by
HIF1α33 (siHIF1α UP), and (iii) genes downregulated by miR-
30d (dy-30d UP, i.e., genes upregulated by dy-30d in MDA-MB-
231 cells). Intersection of these sets returned 118 genes commonly
regulated by mut-p53/HIF1α/miR-30d; ten of these mRNAs are
predicted miR-30d targets in silico (www.targetscan.org) (Fig. 4a).
Validation by RT-qPCR confirmed that mut-p53 represses
AP2A1, DGKZ, IQCG, PPP3CB, and VPS26B through miR-30d
(Fig. 4b and Supplementary Fig. 6a). Interestingly, these genes
have been associated to vesicular trafficking and recycling pro-
cesses. We analyzed the ability of miR-30d to directly down-
regulate these mRNAs by 3′UTR-luciferase reporter assays
(Fig. 4c–d, Supplementary Fig. 5b). We observed reduction of
reporter activity only for DGKZ and VPS26B constructs, that was
prevented by introducing targeted mutations at predicted miR-
30d binding sites, suggesting that DGKZ and VPS26B are direct
targets of miR-30d (Fig. 4d). Consistently, endogenous DGKZ
and VPS26B proteins increased upon mut-p53 depletion in
MDA-MB-231 cells, while miR-30d overexpression reverted this
effect (Supplementary Fig. 6c). Similarly, hypoxic conditions
reduced DGKZ and VPS26B transcripts, while HIF1α knockdown
increased them (Supplementary Fig. 6d).
DGKZ is an enzyme belonging to the diacylglycerol kinase
family44, while VPS26B is a component of the retromer core
complex, which mediates the recycling of proteins during endosomal
sorting45,46. VPS26B and its paralogue VPS26A represent mutually
exclusive subunits that define distinct retromer complexes47. Of
note, mut-p53 and miR-30d regulate specifically VPS26B expression,
while not affecting VPS26A (Supplementary Fig. 6e).
We next investigated the role of DGKZ and VPS26B in GA
morphology. As shown in Fig. 4e, downregulation of either DGKZ
or VPS26B by RNAi induced GA vesiculation in MCF10A cells,
mimicking miR-30d overexpression. We then analyzed protein
secretion by metabolic labeling: depletion of DGKZ or VPS26B in
MCF10A cells resulted in significant increase of total protein
secretion, similarly to miR-30d overexpression (Fig. 4f, Supple-
mentary Fig. 6f).
By catalyzing the conversion of membrane lipid diacylglycerol
(DAG) in phosphatidic acid, DGKZ decreases the levels of DAG
at membranes44. The local concentration of DAG regulates Golgi
tubulo-vesiculation48 and promotes trafficking from trans-Golgi
to plasma membrane via activation of Golgi resident PKD
kinase49,50. We thus hypothesized that downregulation of DGKZ
by miR-30d may lead to DAG accumulation at Golgi membranes
inducing local PKD activation. We tested this possibility using a
fluorescent probe consisting of the DAG-binding domain of
PKCγ fused to GFP51. In MDA-MB-231 cells, mut-p53 knock-
down reduced DAG levels at cis- and trans-Golgi, while
concomitant miR-30d overexpression rescued DAG accumula-
tion (Supplementary Fig. 6g). We then monitored PKD1
activation upon mut-p53 knockdown, observing a reduction of
the active phosphorylated form of PKD1 both in total cell lysates
and specifically at Golgi membranes as indicated by immuno-
fluorescence and confocal imaging, while either miR-30d over-
expression or DGKZ knockdown reversed this effect (Fig. 4g). It
is thus conceivable that DAG accumulation and consequent
activation of PKD contribute to the ability of mut-p53/miR-30d
to enhance secretion.
miR-30d has been previously reported to reduce expression of
the Golgi GalNAc transferase GALNT7, affecting O-glycosylation
and promoting invasion and metastasis of melanoma cells21. We
confirmed that miR-30d reduced GALNT7 expression also in
MDA-MB-231 cells (Supplementary Fig. 6i). However, GALNT7
depletion in MCF10A cells did neither cause GA vesiculation
(Supplementary Fig. 6j), nor enhanced ssGFP secretion (Supple-
mentary Fig. 6k), suggesting that its downregulation does not
contribute to GA alteration by miR-30d.
Altogether, these findings identify DGKZ and VPS26B as direct
targets of mut-p53/miR-30d axis, whose inhibition contributes to
GA vesiculation and increased secretion. Moreover, these data
suggest that DGKZ inhibition by miR-30d influences GA
morphology and function by altering DAG-dependent signaling.
Interestingly, also indirect effects of miR-30d, particularly
microtubule stabilization (as judged by staining for acetylated
tubulin shown in Supplementary Fig. 6l), may promote secretion.
In fact, the microtubule stabilizing agent Taxol, which increases
Golgi vesiculation and protein secretion (Supplementary Fig. 6l-
m), partially rescues ssGFP secretion upon miR-30d inhibition in
MDA-MB-231 cells (Supplementary Fig. 6m).
Mut-p53/miR-30d secretome impacts on tumor micro-
environment. We then investigated the functional relevance of
altered secretion by mut-p53/miR-30d. Bioinformatic analysis of
mut-p53/miR-30d secretome (Fig. 5a) revealed enrichment of
ECM composition and remodeling, cell–ECM and cell–cell
adhesion, angiogenesis and migration functional categories
(Fig. 5a, Supplementary Data File 2).
This prompted us to explore whether secretome reprogram-
ming could affect the crosstalk of cancer cells with their
microenvironment. In particular, altered ECM deposition and
remodeling increases stromal stiffness and affects mechanosignal-
ing, altering the activity of CAFs and other cells populating the
TME4. Immunoblot analysis of MDA-MB-231 CM highlighted
that mut-p53 knockdown reduced secreted ECM components
including Fibronectin, Laminin V and Laminin B1, while miR-
30d overexpression increased them (Fig. 5b, Supplementary
Fig. 7a). Accordingly, using atomic force microscopy we found
that mut-p53 knockdown in MDA-MB-231 cells decreased ECM
rigidity (0.15 kPa vs 0.25 kPa), while miR-30d overexpression
induced a stiffer ECM (0.30 kPA) (Fig. 5c and Supplementary
Fig. 7b).
Next, we evaluated paracrine effects of mut-p53/miR-30d
secretome on tumor and stromal cells, including fibroblasts and
endothelial cells. To evaluate the impact on cancer cell migration,
H1299 lung cancer cells were treated with CMs collected from
either H1299 or MDA-MB-231 cells. As shown in Fig. 5d, CM
from MDA-MB-231 cells increased migration of H1299 cells
more than twofold, an effect significantly reduced upon depleting
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Fig. 4 miR-30d alters the secretory pathway via DGKZ and VPS26B. a Venn diagram illustrating the overlap between transcripts upregulated by miR-30d
inhibition (decoy-miR-30d UP), mut-p53 depletion (sip53 UP30), and HIF1α depletion (siHIF1a UP33) in the MDA-MB-231 cell line. Common genes that are
predicted miR-30d targets by TargetScan algorithm are listed. b Expression of indicated mRNAs in MDA-MB-231 cells transfected with either miR-30d
mimic, mut-p53 siRNA, or their combination was analyzed by RT-qPCR, normalized to H3 expression. c Top: miR-30d sequence. Bottom: sequences of the 3′
UTR regions of DGKZ and VPS26B. The miR-30d seed sequences are underlined, mutagenized sequences in the constructs are indicated in red. d Luciferase
assays were performed in H1299 cells with reporter plasmids as described in (c); reporter plasmids were co-transfected with control (CTRL) or miR-30d
expression constructs. Firefly luciferase expressed by the same plasmid was used to normalize for transfection efficiency. e Immunofluorescence analysis of
Golgi morphology by staining for GM130 in MCF10A cells upon overexpressing miR-30d mimic or silencing DGKZ or VPS26B. Nuclei were stained with
Hoechst. Scale bar, 20 µm. The graph shows the percentage of cells with vesiculated Golgi structure upon different treatments. f Analysis of total protein
secretion in MCF10A cells after overexpression of miR-30d mimic, or silencing of DGKZ or VPS26B, and metabolically labeled with [35S]-methionine/
cysteine aminoacids. Labeled proteins were resolved by SDS-PAGE and detected by autoradiography (representative of n= 3 biological replicates).
Treatment with 2.5 μM BFA was used as a control. Right: graph showing the ratio of secreted versus intracellular labeled proteins quantified by densitometry
(corresponding intracellular proteins are shown in Supplementary Fig. 4f). g Co-localization of phosphorylated PKD (pPKD) with the Golgi marker GM130 in
MDA-MB-231 cells upon mut-p53 knockdown (sip53), and either introduction of miR-30d mimic or DGKZ silencing (siDGKZ). Scale bar, 20 µm. The
bloxplot shows the Pearson’s correlation coefficient for pPKD Golgi localization (n= 25 cells for each condition), median and whiskers calculated with Tukey
method. Graphs represent the individual data points, mean+/− SEM of three independent experiments. P value (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001) was calculated by two-tailed unpaired Student’s t-test). Source data are provided as Source data file.
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Fig. 5 The mut-p53/miR-30d secretome induces a supportive TME. a GO enrichment analysis of differentially secreted proteins (Fig. 2g data), using DAVID
database. All terms were significant (p < 0.05 Benjamini–Hochberg correction). b Analysis of intracellular (cell lysates) and secreted (CM) proteins in MDA-
MB-231 cells transfected with mut-p53 siRNA (sip53) alone or with miR-30d mimic. c AFM measurement of the stiffness of ECM deposited by MDA-MB-231
cells transfected with mut-p53 siRNA alone or with miR-30d mimic. Boxplot represents median and whiskers (Tukey method). d H1299 cells were treated with
H1299-conditioned DMEM or conditioned DMEM (CM) from MDA-MB-231 cells transfected as in (b); cell migration was analyzed by transwelling (Boyden
chamber) assays (16 h). Right: cell amounts and mut-p53 levels were compared by western blot. Bottom: Representative light microscope images of migrated
cells. e H1299 cell migration analysis performed as in (d), using CM from MDA-MB-231 cells transduced with control (CTRL) or dy-30d. Control of decoy
vector was GFP. f Levels of intracellular and secreted VEGFA analyzed as in (b). Right: relative VEGFA secretion quantified by densitometry. g Analysis of
endothelial network formation by HUVEC cells on Matrigel upon addition of CM from MDA-MB-231 cells transfected as in (b). The graph shows numbers of
endothelial closed loops (n= 4). VEGF (20 ng/ml for 24 h) was used as control. h Dextran permeability assay of HUVEC monolayers was performed upon
addition in the upper chamber of MDA-MB-231 CM as in (b). FITC-Dextran fluorescence in the lower chamber was measured after 30′. TNFα (100 ng/ml for
30min) was used as control. i Representative light microscopy images of wound healing assays of WI-38 fibroblasts treated with their medium (CTRL) or with
MDA-MB-231 CM as in (d). The graph shows percentage of wound closure. j Immunoblot analysis of fibronectin1 in WI-38 cells treated as in (i). The blot is
representative of n= 3 biological replicates. Bottom: densitometry quantification of FN1 expression relative to GAPDH. Graphs represent individual data points
and mean+/− SEM; p value (*p < 0.05, **p < 0.01. ***p < 0.001, ****p < 0.0001) calculated by two-tailed unpaired Student’s t-test. Blots are representative of n
= 3 biological replicates. Source data are provided as Source data file.
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mut-p53 in donor cells. Overexpression of miR-30d was sufficient
to restore a pro-migratory secretion in mut-p53-KD MDA-MB-
231 cells (Fig. 5d). Similarly, inhibition of miR-30d abolished the
pro-migratory effect of MDA-MB-231 CM on H1299 cells
(Fig. 5e). Of note, this property relied on the protein component
of the secretome, since it was abolished by heat denaturation
(Supplementary Fig. 7c).
Next, we analyzed the impact of mut-p53/miR-30d secretome on
endothelial cells and fibroblasts. Mut-p53 directly promotes VEGFA
transcription52 (Supplementary Fig. 7d), and consistently with
secretome analysis mut-p53 enhanced secretion of this proangio-
genic factor in MDA-MB-231 cells also via miR-30d (Fig. 5f). We
evaluated the effect of mut-p53/miR-30d secretome on endothelial
cells by performing angiogenesis and vascular permeability assays
in vitro using Human Umbilical Vein Endothelial Cells (HUVEC).
Preconditioning with MDA-MB-231 CM increased both the
number of HUVEC closed loops, and permeability to Dextran of
HUVEC monolayers, indicating increased angiogenesis and
endothelial leakiness. Both effects were reduced by mut-p53
knockdown and recovered by miR-30d overexpression in mut-
p53-KD cells (Fig. 5g, Supplementary Fig. 7e, Fig. 5h).
We then evaluated the effect of the mut-p53/miR-30d secretome
on the activation of BJ and Wi-38 normal-like human fibroblasts in
wound healing assays. Preconditioning with CM obtained from
MDA-MB-231 or MDA-MB-468 cells enhanced fibroblast migra-
tion and wound closure; these effects were dampened upon
silencing mut-p53 in donor cells, and were recovered by miR-30d
overexpression (Fig. 5i; Supplementary Fig. 8a-b). In addition,
preconditioning BJ cells with CM from MDA-MB-231 cells grown
under hypoxia further enhanced fibroblast migration and wound
closure, and these effects were reduced by miR-30d inhibition in
donor cells (Supplementary Fig. 8c). Importantly, inhibiting
secretion in mut-p53 expressing donor cells by BFA treatment
abolished their pro-migratory effect (Supplementary Fig. 8d). We
also observed induction of active cancer-associated fibroblasts
(CAFs) markers53 including fibronectin, α-SMA, HIF, and YAP in
Wi-38 fibroblasts treated with MDA-MB-231 CM, in a mut-p53/
miR-30d-dependent manner (Fig. 5j, Supplementary Fig. 8e-g),
indicating that this axis causes functional and metabolic activation
of CAFs. Finally, we tested whether this effect of miR-30d required
downregulation of DGKZ and VPS26B. Inhibition of miR-30d in
MDA-MB-231 cells increased DGKZ and VPS26B expression and
concomitantly reduced paracrine stimulation of fibroblast migra-
tion. In this context, silencing either DGKZ or VPS26B in MDA-
MB-231/miR-30d-dy cells partially restored induction of CAFs
migration and wound closure (Supplementary Fig. 8h), confirming
that miR-30d promotes CAFs recruitment at least in part via
inhibiting these targets.
These results suggest that mut-p53/miR-30d secretome could
act locally in a paracrine fashion on tumor and stromal cell
populations, both via inducing ECM deposition and remodeling
and via signaling by secreted soluble factors.
miR-30d enhances tumorigenesis and metastasis in vivo. To
investigate the impact of miR-30d-dependent secretome on
tumor growth and metastasis in vivo, immunodeficient mice were
orthotopically injected with luciferase-expressing MDA-MB-231
cells (MDA-MB-231–LUC), stably transduced with either control
or dy-30d construct. Inhibition of miR-30d significantly delayed
tumor growth over a 4 weeks period (Fig. 6a).
Of note, immunoblot analysis of primary tumors from
engrafted mice highlighted increased expression of DGKZ and
VPS26B and reduction of PDIA5, Sec24A, β-COP, and GM130
upon miR-30d inhibition, suggesting decreased secretory traffick-
ing (Supplementary Fig. 9a).
Immunohistochemical analysis of GM130 highlighted enlarged
Golgi in primary tumors derived from control mice, while miR-
30d inhibition was associated with regular perinuclear Golgi
(Fig. 6b). Consistently, analysis of tumor stroma highlighted that
miR-30d inhibition strongly decreased ECM deposition/remodel-
ing and CAFs recruitment, as judged by Picro Sirius red and
αSMA staining, respectively (Fig. 6c, d). These data suggest a key
role of miR-30d in the ability of mut-p53 to support cancer
growth by paracrine effects on tumor stroma.
We then evaluated metastatic dissemination by whole-body
bioluminescence imaging. We observed a strong reduction of
lung metastasis in mice grafted with cells expressing dy-30d as
compared with control, even when primary tumors had similar
size (Fig. 6e, compare primary tumor and metastasis dimension
of CTRL 28 days vs dy-30d 35 days). We also analyzed the impact
of miR-30d on metastatic colonization by injecting control- or
dy-30d MDA-MB-231–LUC cells intravenously. Total body and
ex vivo lung bioluminescence imaging showed that lung
colonization was dramatically reduced by inhibiting miR-30d
(Fig. 6f–g).
Recent evidence suggests that factors secreted by primary tumors
may create a permissive microenvironment for metastasis coloniza-
tion at secondary sites1. Hence, we asked whether miR-30d may
contribute to systemic effects of the primary tumor secretome. We
pre-conditioned immunocompromised mice with 10 daily intra-
peritoneal injections of CM from MDA-MB-231 cells transfected
with either IH-30d or control hairpin, prior to engraftment with
MDA-MB-231–LUC cells in the mammary fat pad. Since primary
tumor growth precludes analysis of secondary lesions, we
monitored metastasis growth for 16 days after surgical resection
of primary tumors as described54 (Fig. 6h). Bioluminescence
imaging and Ki67 immunohistochemistry highlighted a reduction
of metastatic lung colonization upon preconditioning animals with
CM derived from IH-30d cells as compared with control (Fig. 6i),
with no significant effect on primary tumor growth (Supplementary
Fig. 9b). Of note, inspection of metastatic lungs of mice treated with
CM from IH-30d cells highlighted reduction of CAFs recruitment,
ECM deposition/remodeling and formation of aberrant vessels, as
judged by αSMA, Picro Sirius red, and CD31 staining, respectively
(Fig. 6j–n). These data suggest that the secretome of mut-p53-
expressing cells contributes to generate a permissive microenviron-
ment for metastatic colonization.
We next evaluated the functional impact of the mut-p53/miR-
30d axis in human samples. We examined adult primary
fibroblasts from two Li-Fraumeni patients, bearing TP53 muta-
tion R248Q, as compared with fibroblasts of two wt-p53 healthy
donors. As shown in Fig. 7a, b, mut-p53 expression was
associated to increased HIF1α and miR-30d levels, reduced
mRNA and protein levels of VPS26B and DGKZ, vesiculated GA
(Fig. 7c) and enhanced protein secretion as evaluated by ssGFP
(Fig. 7d). Consistently, inhibition of miR-30d dampened secretion
in mut-p53 expressing cells (Fig. 7d). These results confirm that
the mut-p53/miR-30d axis modifies GA structure and leads to
increased secretion also in Li-Fraumeni primary cells, a unique
genetic model to study mut-p53 activities in non-neoplastic
human tissues9.
To confirm our findings in established human tumors, miR-
30d expression was analyzed by BaseScope in situ hybridization
and quantification in tissue sections of invasive ductal breast
cancers (n= 12). These were identified as either p53-high cases,
bearing hotspot missense TP53 mutations as indicated by
Competitive Allele-Specific TaqMan PCR (Supplementary
Table 1) and high mut-p53 expression as indicated by
immunohistochemistry, or p53-low cases, which displayed no
hotspot TP53 mutations and low or null p53 expression. As
shown in Fig. 7e, p53-high samples displayed higher miR-30d
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Fig. 6 miR-30d enhances tumorigenesis and metastasis in vivo. a Tumor volume measured at the indicated time points after orthotopic xenograft of
MDA-MB-231–Luc control (CTRL, n= 8) or miR-30d decoy (dy-30d, n= 9) cells in SCID mice. p value: p= 0.00255667, p= 0.00021304, p=
0.00000072, and p= 0.00000029, respectively, at 7, 14, 21, and 28 days. b Representative images of immunohistochemical analyses (IHC) of markers of
Golgi (GM130), collagen deposition (Picro Sirius red), and CAFs (α-SMA) in serial sections from primary tumors in (a) (CTRL, n= 8; dy-30d, n= 9). Lower
panels show higher magnification of upper panels’ insets. c, d Quantification of immunohistochemistry markers analyzed in (c). e In vivo luciferase
quantification of lung metastases from mice in (a). (a) and (b) report the mean+/− SEM with CTRL (n= 8) and decoy-30d (n= 9) (p value: p= 0.0011
and p= 0.0265, respectively, at 28 and 35 days). f Whole-body in vivo luciferase quantification at the indicated time points of control or miR-30d decoy
MDA-MB-231–Luc cells injected intravenously in SCID mice (CTRL n= 6, dy-30d n= 9, p= 0.0011134, p= 0.0000023, respectively, at 21 and 28 days).
g Ex vivo luciferase quantification at 28 days in lungs explanted from mice in (d) (CTRL n= 6, dy-30d n= 9, p= 0.0004). h Schematic representation of
the mouse conditioning experiment. SCID mice were injected with medium conditioned by MDA-MB-231 cells transfected with control or miR-30d
inhibitor (IH-30d), before performing orthotopic xenografts. Metastases were evaluated after resection of primary tumors. i Confidence lines showing
whole-body growth of metastases at the indicated days after surgical removal of primary tumors (Wilcoxon rank-sum test; n= 8 for each group).
j Representative images of immunohistochemical (IHC) analyses for markers of proliferation (Ki67), collagen deposition (Picro Sirius red), CAFs (α-SMA),
and endothelial cells (CD31), in metastases from serial lung sections of mice in (h) and (i) (n= 8 for each group). Lower panels show magnification of
insets in the upper panels. k–n Quantification of immunohistochemistry markers reported in (j). All graphs report single data points, mean+/− SEM (p
value: *p < 0.05, ***p < 0.001, ****p < 0.0001 by two-tailed unpaired Student’s t-test). Source data are provided as Source data file.
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expression, enlarged Golgi judged by GM130 immunostaining
(Fig. 7f) and higher Sec24A and β-COP immunostaining,
suggesting enhanced secretory trafficking (Fig. 7g, h). In p53-
high cases we also observed upregulation of specific components
of mut-p53 dependent secretome (Col6A, Frem2, and Lamb3)
(Fig. 7i–k).
Altogether these data support a role of the mut-p53/miR-30d
axis in promoting cancer progression and metastasis via an
altered secretome, exerting paracrine effects on the TME both at
primary and distant sites (Fig. 8).
Discussion
In this work we demonstrate that missense p53 mutants, via tran-
scriptional induction of miR-30d, cause structural modifications of
the GA, leading to enhanced secretory trafficking and release of a
pro-malignant secretome that modifies the TME. We discovered
that mut-p53 induces miR-30d expression by hijacking HIF1α in
both hypoxic and normoxic contexts. Activated HIF1α can induce
miR-30d also in the absence of mut-p53, implying that hypoxia and
other HIF1-inducing stimuli may alter GA structure and secretory
trafficking via miR-30d also in tumors lacking mut-p53.
In physiological contexts, increased secretion associates with
structural adaptations of trafficking hubs, i.e., enlargement of the
ER6,55 and tubulo-vesiculation of the GA39. It is conceivable that
oncogenes may exploit these programs to enhance secretion in
cancer cells. Indeed, alterations of the GA and expansion of Golgi
network have been observed in cancer cells with high tumorigenic
potential7,56, and upregulation of an ER-Golgi trafficking gene
signature correlates with breast cancer metastasis8. We discovered
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Fig. 7 Impact of mut-p53/miR-30d axis in clinical samples. a Analysis of DGKZ, VPS26B, and p53 protein levels in Human Primary Fibroblasts with
different p53 status as indicated. HSP90 was used as loading control. The blot is representative of n= 3 biological replicates. b miR-30d, DGKZ, and
VPS26B expression was evaluated in Human Primary Fibroblasts with different p53 status as indicated by RT-qPCR, normalized to U6B and H3 RNA
expression levels. Exact p values are indicated in the figure. c Immunofluorescence analysis of Golgi apparatus stained with an antibody specific for GM130
in human primary fibroblasts with different TP53 status as indicated. Right: graph showing the percentage of cells with vesiculated Golgi upon different
treatments. d Human Primary Fibroblasts with the indicated TP53 status were transfected with a plasmid encoding green fluorescent protein fused to a
secretion signal sequence (ssGFP). Intracellular (cells) and extracellular (medium) GFP protein levels were analyzed upon transfection of miR-30d inhibitor
(IH-30d). Forty-eight hours upon silencing, fresh medium was added to the cells and collected after 2 h for analysis. Treatment with BFA 2.5 μM for 2 h was
included as control. Densitometric quantification of the ratio of secreted versus intracellular ssGFP is shown in the graph below. All blots are representative
of n= 3 biological replicates. Exact p values are indicated in the figure. e–k Representative images of immunohistochemical (IHC) analysis of breast cancer
samples divided on the basis of p53 missense mutation as inferred by p53 staining and allele-specific PCR (n= 6 for each condition). Samples were stained
with anti-p53 antibody combined with miR-30d in situ hybridization by BaseScope (e) or with anti-GM130 (f), anti-Sec24A (g), anti-β-COP (h), Collagen-
VI A2 (i), FREM2 (j), or LAMB3 (k) antibodies. The graphs below report the relative quantification of the antigens analyzed. All graphs report single data
points, mean+/− SEM; p value (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) was calculated by two-tailed unpaired Student’s t-test. Blots are
representative of n= 3 biological replicates. Source data are provided as Source data file.
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that the mut-p53/miR-30d axis promotes formation of tubular
continuities across Golgi cisternae, resulting in rapid diffusion of
cargoes and increased secretion. Mechanistically, we demon-
strated that miR-30d affects GA structure in part via direct
downregulation of the DGKZ and VPS26B targets, that have been
previously linked to modulation of GA structure and secretion.
Inhibition of DGKZ kinase by miR-30d leads to accumulation of
the polar lipid DAG in Golgi membranes. DAG impacts multiple
aspects of Golgi transport and secretory pathway, including GA
tubulo-vesiculation48,57. Indeed, thanks to its conical shape49,50
and to its function as second messenger activating PKD/PKCη
kinases58, DAG modulates membrane curvature facilitating
vesicular transport and secretion. The second target, VPS26B, is a
component of the core retromer complex. Defects in retromer
function attenuate retrograde transport from endosomes to the
trans-Golgi network46,59: this may induce GA structural and
functional alterations as well as inappropriate sorting and recy-
cling activities of endosomes that may lead to increased secretion,
as demonstrated for cathepsin-D precursor60, and Aβ in Alz-
heimer’s disease61.
In addition, we observed that miR-30d promotes secretion also
by inducing microtubule stability, possibly via indirect effects on
kinesins involved in dynamic assembly of Golgi mini-stacks62,63.
Mut-p53 has been found to upregulate several soluble media-
tors that promote cancer cell migration and invasion through
autocrine or paracrine signaling15,64. Our data show that, in
addition to regulating the expression of soluble molecules and
ECM components in concert with HIF1α65 and other transcrip-
tion factors, mut-p53 enhances the whole secretion process, thus
enforcing the release of a malignant secretome acting on the
TME. Several proteins in the mut-p53 secretome can affect ECM
composition and remodeling, contributing to metastatic spread4.
Accordingly, we observed that the mut-p53/miR-30d-dependent
secretome promotes ECM deposition and stiffening, and sustains
functional activation of CAFs both at primary and secondary
tumor sites. Of note, both mut-p53 and HIF1α are mechan-
osensitive factors, activated downstream to actomyosin dynamics
induced by a rigid ECM14,66, and consistently we observed that
elevated ECM stiffness increases miR-30d expression and cancer
cell secretion. Thus, the mut-p53/HIF1α/miR-30d pathway
establishes a vicious cycle that reacts to mechanical cues and, via
enhanced secretion, further strengthens these inputs in the TME,
increasing tumor aggressiveness, promoting CAF activation and
stromal neo-vascularization. These activities contribute to build a
supportive tumor stroma at the primary tumor site and at
metastatic niches, accelerating the timing of metastasis in vivo. Of
note, mouse preconditioning experiments demonstrated that
cancer cells deficient for miR-30d expression release a secretome
that is unable to support metastatic colonization.
Importantly, we provide evidence that the p53/HIF1α/miR-30d
axis contributes to human carcinogenesis, and suggest new
potential non-invasive biomarkers and tractable targets to blunt
tumor aggressiveness. Interestingly, drugs targeting the GA and
secretory pathway are under preclinical study to control tumor
growth and dissemination67. Our work unveils an oncogene-
induced mechanism that offers several actionable targets. Options
include interfering with HIF1α function68,69, blunting mut-p53
gain of function, either through inhibition of the mevalonate/
RhoA pathway14 or other mut-p53 inhibitors (e.g., PRIMA-1Met,
Hsp90 inhibitors)26,70 or directly targeting miR-30d. In sum,
alteration of Golgi structure and function by mut-p53 and HIF1α
oncogenes confers selective advantages to primary tumor and
metastasis, and may be considered as a valuable target for more
efficient cancer therapies.
Methods
Contact and reagent resource sharing. Further information and requests for
resources and reagents should be directed to and will be fulfilled by the Lead














Fig. 8 Model. Schematic model of the impact of mut-p53/miR-30d axis on Golgi Apparatus, secretory trafficking and of its paracrine effect on tumor
microenvironment.
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Human sample collection and patient information. Human Primary Fibroblasts
were obtained by skin biopsy samples collected at The Hospital for Sick Children,
Toronto, Ontario, Canada Institutional Research (TP53 mutant, n= 2; TP53 wild-
type, n= 2). Informed consent was obtained from the patient or parent/legal
guardian of the patient. Ethics Board approval was obtained for the study, under
the study title “Molecular characterization of Li-Fraumeni Syndrome and its
variants”.
Human breast cancer tissue sections were selected from the archival samples of
the Tumor Immunology Laboratory, Human Pathology Section, of the Department
of Health Sciences, University of Palermo. The cases were classified according to
the World Health Organization classification criteria of the Tumors of the Breast
(2013). Samples were collected in accordance with the Helsinki Declaration, and
the study was approved by the University of Palermo Ethical Review Board
(approval number 09/2018).
Cell culture. MDA-MB-231, MDA-MB-468, SUM-159PT, SK-BR-3, HT-29, HEK-
293T, and HEK-293GP cells were cultured in DMEM medium supplemented with
10% FBS (Fetal Bovine Serum). H1299, DU 145 and TOV-112D cells were cultured in
RPMI medium with 10% FBS. MCF10A cells were maintained in DMEM/Ham’s F12
medium in a 1:1 ratio, supplemented with 5% HS (Horse Serum), insulin (10 μg/ml),
hydrocortisone (0.5 μg/ml), and epidermal growth factor (EGF, 20 ng/ml). Mahlavu
cells were cultured in EMEM medium supplemented with 10% FBS, 1% MEM NEAA
(Minimum Essential Medium Non-Essential Amino Acids) and 1% Glutamax.
BJ-EHT-ER-RAS were obtained from R. Agami71 and cultured in DMEM
medium supplemented with 10% FBS. WI-38 cells were cultured in EMEM
medium supplemented with 10% FBS and 1% MEM NEAA. HUVEC (Human
Umbilical Vein Endothelial Cells) were kindly isolated by Dr. Chiara Agostinis as
previously described72 and provided by Prof. Roberta Bulla, Università degli Studi
di Trieste, Trieste, Italy. The cells were seeded in plates coated with fibronectin and
maintained in Human Endothelial SFM supplemented with 20 ng/ml bFGF (basic
Fibroblast Growth Factor), 10 ng/ml EGF, and 10% FBS. All the experiments with
HUVECs were carried out by the fourth cell culture passage.
The LFS fibroblast lines were cultured in AMEM (Wisent #310-022-CL)
supplemented with 10% FBS and passaged with 0.05% Trypsin (Wisent #325-542-
EL).
All media were supplemented with penicillin and streptomycin (100 IU/mL
each). All the cells described were maintained in a 37 °C, 5% CO2 incubator.
Hypoxic conditions were obtained culturing cells in a 37 °C, 5% CO2, 2% O2
incubator balanced with N2, or treating cells with 150 μM of CoCl2 for 16–24 h. To
mimic differential substrate stiffness culturing conditions, MDA-MB-231 cells were
seeded on top of fibronectin-coated 50 or 0.5 kPa Easy Coat hydrogels (Cell
Guidance Systems).
Three-dimensional culture was carried out as previously described73. In brief,
24-wells dishes were lined with growth factor-reduced Matrigel, and cells were
seeded in DMEM medium supplemented with 1% FBS, 250 ng/ml insulin, 0.5 μg/ml
hydrocortisone, and 3% Matrigel for 8 days.
MDA-MB-231 cells, stably expressing TWEEN-EGFP-3′UTR (as control
vector) or TWEEN-EGFP-decoy-miR-30d, were maintained with the addition of
puromycin to the growth medium (2 μg/ml).
MCF10A, stably expressing pSR-Blast-empty (as a control vector) or miR-Vec-
30d were maintained with addition of blasticidin to the growth medium (2 μg/ml).
MCF 10A stably silenced for endogenous wt-p53 (shp53), and overexpressing
mut-p53 R175H, mut-p53 R280K, or mut-p53 R273H were selected and
maintained with addition of puromycin and blasticidin to the growth medium (2
μg/ml each).
Transfection and viral transduction. Cells were transfected when the culture
reached 50–80% confluence level. For DNA transfections, the appropriate
amount of DNA, depending on the total surface of the culture vessel, was used
together with Lipofectamine 2000 or LTX transfection reagents, following
manufacturer’s instructions; for siRNA/miRNA mimic transfections, cells were
transfected with 40 nM siRNA oligonucleotides, 3 nM miRNA mimics, or 20 nM
miRNA inhibitor harpin together with Lipofectamine RNAiMax following
manufacturer’s instructions; as a negative control, the Qiagen AllStars Negative
Control siRNA was used. siRNA sequences are listed in Supplementary Table 2.
For retrovirus production, low-confluence HEK-293GP packaging cells were
transfected using calcium phosphate with the appropriate plasmids in
combination with the pMD2.G packaging vector. For lentivirus production, low-
confluence HEK-293T packaging cells were transfected using calcium phosphate
with the appropriate plasmids in combination with the pMD2.G and psPAX2
packaging vectors. After 48–72 h, the virus-containing medium was collected
and filtered with 0.45 syringe filter to remouve cellular debris, and was added to
the target cells, which were then selected with puromycin and/or blasticidin, 2
μg/ml each.
Plasmids. pRS-shp53 and pRS vectors were kindly provided by R. Agami. miR-Vec
constructs were part of the miR-Lib, provided in collaboration by R. Agami74.
pLPC-ssGFP was obtained fusing the rat FSHb signal peptide75 upstream of the
eGFP gene in the pLPC construct.
GFP-C1-PKCgamma-C1A was a gift from Tobias Meyer (Addgene plasmid #
21205; http://n2t.net/addgene:21205; RRID:Addgene_21205)51.
psiCHECK2 3′UTR reporter constructs were obtained by cloning each 3′UTR
into the psiCHECK2 (Promega) plasmid, downstream of Renilla Luciferase
reporter gene, between NotI and XhoI restriction sites. The psiCHECK2 vector also
expresses Firefly Luciferase, which is used to normalize for the efficiency of plasmid
transfection. The 3′UTRs sequences of AP2A1, DGKZ, IQCG, PPP3CB, and
VPS26B were obtained from Ensembl (http://www.ensembl.org/index.html) and
UCSC (http://genome.ucsc.edu/cgibin/hgGateway) database and amplified from
MDA-MB-231 genomic DNA with AccuPrime™ Taq DNA Polymerase High
Fidelity (Invitrogen), following manufacturer’s instructions. In the psiCHECK2
DGKZ 3′UTR and psiCHECK2 VPS26B 3′UTR reporters, the miR-30d putative
binding sites were mutated by using Quick change II XL Site-Directed Mutagenesis
kit (Stratagene, CAT#200521-5), following manufacturer’s instructions.
The lentiviral vector pTWEEN 3′UTR EGFP empty was kindly provided by R.
De Maria, and the miR-30d decoy was cloned as described by Bonci et al.37. N-
terminally HA-tagged shRNA-resistant p53 constructs: pMSCV-HA-P53 R175H,
P53 R273H, P53 R280K, and pMSCV-HA-P53R were previously described30.
RNA extraction and quantitative real-time PCR. Cells were harvested in Qiazol
lysis reagent (Qiagen) for total RNA extraction, and contaminant DNA was
removed by DNase treatment. qRT-PCR analyses were carried out on cDNAs
retrotranscribed with Quantitect reverse transcription kit (Qiagen), and analyzed
genes were amplified using SsoAdvancedTMSYBR® Green Master Mix (Bio-Rad)
on a CFX96™ Real-Time PCR System (Bio-Rad). For miRNAs and the house-
keeping control genes RNU6B and SNORD25 small nuclear RNA, 0.5 μg of total
RNA were retrotranscribed and amplified with miScript PCR System (Qiagen)
following manufacturer’s instructions. The data were analyzed with the Biorad CFX
Manager software. Experiments were performed at least three times, and each
sample is the average of a technical duplicate. The quantification is based on the
2−ΔΔCt method using the proper housekeeping gene levels as normalization
reference. Primers sequences are reported in the Supplementary Table 2.
Chromatin immunoprecipitation. Chromatin immunoprecipitation was per-
formed as previously described30. Chromatin was immunoprecipitated with the
p53 FL-393 (sc-6243, Santa Cruz Biotechnology) antibody. IgGs purified from
rabbit serum were used as negative control. Co-immunoprecipitated DNA was
analyzed by real-time PCR. Promoter occupancy was calculated as percent of input
chromatin immunoprecipitated using the 2−ΔCt method. Primers sequences are
reported in the Supplemental Table 2.
Microarray data generation. For microarray analysis of genes regulated by miR-
30d, total RNA (2 μg) was isolated from MDA-MB-231 cells expressing miR-30d
decoy or control vector. For each experimental condition, three biological replicates
were prepared and processed in parallel. RNA concentration, quality and purity
were determined using a NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies Inc.). Synthesis of cDNA and biotinylated cRNA (from 500 ng total
RNA) was performed using the Illumina TotalPrep RNA Amplification Kit
(Ambion), according to the manufacturer’s protocol. Quality assessment and
quantification of total RNA and cRNAs were performed with Agilent RNA kits on
a Bioanalyzer 2100 System (Agilent). Hybridization of cRNAs (750 ng) was carried
out using Illumina Human 48 K gene chips (Human HT-12 v4 Expression Bead-
Chip). Array chip washing was performed in High Temp Wash Buffer (Illumina) at
55 °C for 10 min, followed by staining using streptavidin-Cy3 dyes (Amersham
Biosciences). Hybridized arrays were stained and scanned in a BeadStation 500
System (Illumina). GenomeStudio Data Analysis Software’s Gene Expression
Module (GSGX) Version 1.9 was used and cubic spline normalization was applied
to the data. The average signal was used for performing the analysis (“AVG_-
Signal”) using limma in the Biocondoctor. Differentially expressed genes were
identified using Significance Analysis of Microarray algorithm coded in the samr R
package, estimating the percentage of false-positive predictions (FDR).
Protein analysis. To perform western blot analysis, total cell extracts were pre-
pared in lysis buffer (300 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1%
NP-40) supplemented with 1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, and 10 μg/ml
CLAP. Protein concentration was determined with Bio-Rad Protein Assay Reagent
(#500-0006, Bio-Rad). Lysates were resolved by SDS/PAGE and transferred to
nitrocellulose membranes (Millipore). Western blot analysis was performed
according to standard procedures.
Co-IP experiments with endogenous proteins were performed using Co-IP
buffer (150 mM NaCl, 50 mM Tris-HCl pH 8, 1 mM EDTA, 1% NP-40, 10%
Glycerol) supplemented with protease inhibitors as described before. Samples were
cleared by centrifugation for 30 min at 13,000 × g at 4 °C and incubated for 16 h at
4 °C with anti-p53 antibody. After 1 h of incubation with protein G-Sepharose (GE
Healthcare), immunoprecipitates were washed three times in Co-IP buffer,
resuspended in Laemmli sample buffer, and analyzed by western blotting. The
antibodies used are listed in the Supplementary Table 3. Anti-mouse and anti-
rabbit HRPO-conjugated (Sigma-Aldrich) antibodies were used as secondary
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antibodies for Western blot. Bands were quantified by densitometry of
autoradiographic films using FIJI software (NIH Image).
Metabolic labeling. Cells were cultured in DMEM without L-methionine and L-
cysteine for 3 h and then pulsed with 25 μCi/ml of [35S] methionine and cysteine
(EasyTag™ EXPRESS35S Protein Labeling Mix PerkinElmer) for 1 h. The chase was
performed in DMEM containing 0.25 M L-methionine and 0.25M L-cysteine. For
brefeldin-A (BFA) treatment, 2.5 μg/ml of BFA was added to the medium during
all phases of the experiments. Medium and cell lysates were collected as described
below and analyzed by SDS-PAGE followed by autoradiography. Lanes were
quantified calculating the densitometry of autoradiographic film by ImageJ76, and
normalized to the intracellular counterpart.
Preparation of conditioned medium. After 6 h from transfection or 24 h from
seeding, cells were washed twice with PBS, and grown in serum-free medium for
48 h. Conditioned medium (CM) was collected, centrifuged at 2000 × g for 5 min to
remove cells and debris, and filtered through a 0.22 μm syringe filter (EuroClone).
If not used immediately, CM was kept a 4 °C for up to 2 days, or stored at −80 °C
for up to 1 week.
For analysis of secreted proteins, 1 mL of CM was precipitated by addition of
trichloroacetic acid (TCA) (Sigma) to a final concentration of 10% and incubation
at 4 °C overnight. The samples were then centrifuged at 17,900 rcf for 15 min at
4 °C, pellets were resuspended in 0.4 ml 100% chilled acetone, and proteins were
recovered by centrifugation at 17,900 rcf for 10 min at 4 °C, air-dried at RT for
30 min and dissolved in Laemmli Sample Buffer 2x.
Secretome analysis. CM was collected as above, treated with 2% SDS and 0.05 M
DTT in 0.1 M Tris-HCl and boiled for 5 min. Total protein concentration in the
lysates and the peptide contents in the digests (see below) were assayed using a
tryptophan fluorescence based WF-assay in microtiter plate format77. The lysates
were processed using the MED FASP method with modifications as described78.
Briefly, proteins were first cleaved overnight by endoproteinase LysC, and subse-
quently digested with trypsin (enzyme to protein ratio 1:50) for 2 h. Aliquots
containing 5 µg total peptide were concentrated to a volume of ~5 µL and stored at
−20 °C. Analysis of peptide mixtures were performed using a QExactive HF mass
spectrometer (Thermo-Fisher Scientific, Palo Alto). Aliquots containing 2 μg total
peptide were chromatographed on a 50 cm column with 75 µm inner diameter
packed C18 material (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany).
Peptide separation was carried out at 300 nL/min for 45 min using a two-step
acetonitrile gradient 5–40% over the first 35 min and 40–95% for the following 10
min. The temperature of the column oven was 55 °C. The mass spectrometer
operated in data-dependent mode with survey scans acquired at a resolution of
50,000 at m/z 400 (transient time 256 ms). Top 15 most abundant isotope patterns
with charge ≥+2 from the survey scan (300–1650m/z) were selected with an
isolation window of 1.6m/z and fragmented by HCD with normalized collision
energies of 25. The maximum ion injection times for the survey scan and the MS/
MS scans were 20 and 60 ms, respectively. The ion target value for MS1 and
MS2 scan modes was set to 3 × 106 and 105, respectively. The dynamic exclusion
was 25 s and 10 ppm. Spectra were searched using MaxQuant software. Proteins
were quantified by the ‘Total Protein Approach’ (TPA)79.
Bioinformatics workflow for prediction of putative secreted proteins. Secre-
tome data were filtered to select putative secreted proteins using a three-step
bioinformatics pipeline as described in ref. 80. First, from 1401 proteins identified,
those with predicted signal peptides were extracted using SignalP 4.181 with default
D-score cut-offs (372 proteins) and UniProt82 keyword annotation “Signal” (432
proteins), obtaining 450 proteins grouped as “classically” secreted. Of the
remaining hits, those annotated with GO83,84 Cellular Component (GOCC)
“extracellular location” were classified as “non-classically secreted proteins I” (557
proteins), discarding those annotated with GOCC “intracellular location”. The
remaining proteins were analyzed with SecretomeP85, which predicts secretory
proteins following nonclassical, signal peptide-independent mechanisms; proteins
with NN-score >0.5 were grouped as “non-classically secreted proteins II” (35
proteins). Merging the classically and non-classically secreted proteins, a list of
1036 proteins were defined as secreted in MDA-MB-231 cell culture media.
Gene enrichment analysis of the secreted proteins. For secretome analysis, the
differentially secreted proteins were identified performing t-test analysis of calcu-
lated TPA-values. Then, starting the list of 1036 putative secreted proteins, was
filtered including differentially secreted proteins with a Benjamini–Hochberg
adjusted p value ≤0.05 in cells depleted of mutant p53 compared with control cells.
These proteins were further filtered comparing the obtained list of mut-p53-
regulated proteins with the proteins whose basal secretion is restored by miR-30d
reintroduction.
Imaging. Immunofluorescence staining was performed as previously described14.
Briefly, cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, per-
meabilized with Triton 0.1% for 10 min and blocked in FBS 3% in PBS for 30 min.
Antigen recognition was performed by incubating primary antibody for 1 h at
37 °C and with secondary antibody for 30 min at 37 °C (goat anti-mouse and goat
anti-rabbit Alexa Fluor 488, 568, 647, Life Technologies). Nuclei were counter-
stained with Hoechst 33342 (Life Technologies). The antibodies used are listed in
the Supplementary Table 3.
Golgi morphology was analyzed on ~300 cells for each condition/experiment.
To quantify the numbers of Golgi stacks, cells were immunostained with an anti-
GM130 antibody and imaged by LSM510 Meta (Zeiss) confocal microscope. For
three-dimensional (3D) reconstruction, the Z-stack images of 50 cells/condition
were quantified using Volocity image analysis (PerkinElmer).
Analysis of localization of the GFP-C1-PKCgamma-C1A construct, and
endogenous PKD-P with the Golgi apparatus (labeled with anti-GM130) was
performed calculating the Pearson’s r correlation coefficient using the Coloc2 plug-
in from the ImageJ suite76, applying the Costes mask method, in images acquired
with Nikon Eclipse C1si confocal microscope. CLEM analysis was performed as
described86,87.
Proximity ligation assay. MDA-MB-231 cells were seeded on coverslips 48 h prior
to treatment. After hypoxia exposure (2% oxygen for 16 h) or hypoxia-mimetic
treatment (150 µM CoCl2 for 16 h), the cells were washed with PBS and fixed in 4%
paraformaldehyde for 10 min at room temperature, followed by two washes with
PBS. The cells were permeabilized with 0.1% Triton X-100 and washed two
additional times with PBS. The PLA was performed using the Duolink In Situ Red
Starter Kit Mouse/Rabbit (Sigma) according to the manufacturer’s protocol. The
following primary antibodies were used: anti-p53 (p53 FL-393, Santa Cruz Bio-
technology), diluted 1:100; anti-HIF1α (H1alpha67, Novus Bio), diluted 1:50. The
stained coverslips were mounted on slides and visualized with Nikon Eclipse C1si
confocal microscope. Representative images are shown for each biological group.
RUSH system. Standard procedures using RUSH system were as previously
described41. MCF10A cells were transiently transfected with plasmids encoding
both the hook and the reporter by Lipofectamine LTX Reagent (Life Technologies).
40 μM D-biotin final was introduced at time 0 to release the reporter. Images were
acquired using a NIKON Eclipse Ti - Live-cell Imaging system and processed using
the FiJi software76. Single cells were selected used the built-in ImageJ masking tool
and stabilized for instrument-derived shifts employing the Image Stabilizer FiJi
plug-in88. Total fluorescence intensity of the masked Golgi apparatus area was
corrected subtracting the background intensity from an area on identical shape,
and the corrected values were normalized on the initial acquisition frame (t= 0′).
Atomic force microscopy analysis. For ECM stiffness measurement MDA-MB-
231 cells were fixed with 4% paraformaldehyde for 20 min. Nuclei were marked via
haematoxylin staining, while ECM was visualized using the Picro Sirius Red Stain
(Abcam, ab150681). AFM imaging was performed at room temperature on a
Smena AFM (NT-MDT Co., Russia) mounted on an inverted fluorescence
microscope (Nikon Eclipse Ti-U). For each experimental condition, three biolo-
gical replicates were prepared and a total of 135 randomly chosen areas were
measured and analyzed. The cantilever used was a tip-less probe characterized by a
spring constant of about 0.03 nN·nm–1 (HQ:CSC38 cantilevers from MikroMasch
Co), at the end of which a 18-μm diameter silica bead (Thermo-Fisher Scientific)
was glued using UV curable glue (Norland Products Inc.). Force spectroscopy
measurements were performed at constant speed (2.5 μm·s–1) and triggered to a
maximum force applied to the sample of 5 nN. Elastic modulus values, in kPa, were
determined by fitting obtained force/displacement curves with a Hertzian model
for the tip used taking advantage of the NOVA (NT-MDT Co., Russia) control and
analysis software. Statistics and data processing were performed using Igor Pro
software (www.wavemetrics.com) and R statistical computing software (www.R-
project.org). The significance of the differences in the data was established as
equality of probability distributions via the Kolmogorov–Smirnov test.
Selection of microRNA-30d putative targets. RNA sequencing data from MDA-
MB-231 cells with siRNA of mut-p53 were obtained from the GEO dataset
GSE682481, we selected differentially expressed genes as those with a reported
Benjamini–Hochberg adjusted p value ≤0.05. Microarray data from MDA-MB-231
cells with shRNA depletion of HIF1α were obtained from the GEO dataset
GSE339502, we selected as differentially expressed genes the ones with a false
discovery rate (FDR) ≤ 0.05. Microarray data from MDA-MB-231 cells with
functional inhibition of miR-30d function were obtained (see above), and we
selected as differentially expressed genes the ones with a Benjamini–Hochberg
adjusted p value ≤ 0.05. Intersecting the lists of upregulated genes using Venny
(Oliveros, J.C. (2007–2015) http://bioinfogp.cnb.csic.es/tools/venny/index.html),
112 genes that were upregulated by mutant p53 depletion, HIF1α depletion, or
miR-30d functional inhibition were obtained. This list was then intersected with
the 1569 genes that are predicted as miR-30d targets by TargetScan (http://www.
targetscan.org/vert_71/4)89, obtaining the 10 genes shown in Fig. 4a.
Luciferase assays. H1299 cells were seeded in 60-mm dishes, and transfected with
2 µg of psiCHECK2 3′UTR reporter vectors. After 24 h the cells were splitted in two
plates, and transfected either with 3 nM of miR-30d-mimic or with miR-Negative
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Control. Six hours after transfection, medium was changed and 18 h later luciferase
activity was measured using the Dual-Luciferase® Reporter Assay System (Pro-
mega) on a Promega luminometer. Relative Luciferase Units (RLU) were calculated
by normalizing the luciferase units measured for the renilla (Renilla reniformis)
luciferase on the luciferase units of the firefly (Photinus phyralis) luciferase in each
sample.
Capillary-like tubules formation assay. Tube formation assay was performed as
previously described72. HUVECs were placed on wells coated with Matrigel
(Becton Dickinson) and incubated for 24 h with VEGF (20 ng/mL) or CM from
different conditions to allow tube formation. After fixation with 4% paraf-
ormaldehyde and staining with Phalloidin-Alexa Fluor 488 (Invitrogen), the
number of tubules was counted under a Leica AF6500 microscope using LAS
software (Leica).
Dextran permeability assay. HUVECs were seeded onto fibronectin-coated
transwell inserts (0.4-μm pore size; Corning). When cells were confluent, they were
pre-treated for 24 h with CM from different conditions, or for 30 min with TNF-α
(100 ng/ml, Invitrogen). FITC-dextran (1 mg/ml, 70 kDa, Sigma) was added to the
monolayer (upper chamber) for 30 min. The presence of FITC-dextran in the lower
chamber was assayed using Enspire multimode plate reader (PerkinElmer).
Fluorescence intensity measurements at 495 nm were expressed as relative per-
meability by calculating the fold increase over the basal permeability of untreated
monolayer (control).
Wound healing assay. Equal numbers of BJ-EHT-ER-RAS or WI-38 cells were
grown in 6-well or 12-well plates until they reached confluence. Then, cells were
scraped with a pipette tip and, after washing with PBS, were incubated with CM
from different conditions, or serum-free medium as a control. For each experi-
mental point, two or three scratch were performed; one image of each wounding
area was acquired immediately after scratching, and then in the same field after
16 h of migration. The relative wound closure was quantified by measuring the
wound area at the time of scratching and at the end point of the experiment using
ImageJ76.
For the experiments performed with WI-38, CM or control medium (DMEM)
was diluted 1:1 in the basal medium for culture of WI-38 cells.
Migration assay. H1299 cells were grown in 6-well plates in the presence of CM
(supplemented with 10% FBS) for 48–72 h. Then 5 × 104 cells were seeded in 24-
well PET inserts (8.0 μm pore size, Falcon) in the presence of CM (supplemented
with 1% FBS) in both compartments. After 16 h, cells on the upper part of the
membrane were removed with a cotton swab and cells that passed through the filter
were fixed in 4% PFA, stained with 0.05% crystal violet and counted.
For the migration assay performed with boiled conditioned medium, CM was
first heat-inactivated at 95 °C for 10 min as previously described90, and then used
according to the procedure above described.
In vivo xenograft experiments. MDA-MB-231 cells were transduced with a
lentiviral vector coding for the firefly (Photinus phyralis) luciferase reporter gene,
produced in HEK-293T cells. Six- to eight-week-old female NOD/SCID common γ
chain knockout (NSG, Charles River) mice were either injected in mammary fat
pad with 1 million of cells, or with 100,000 cells intravenously. Orthotopic tumor
growth was monitored by caliper measurements and the volume was calculated
using the formula: tumor volume (mm3)=D × d2/2, where D and d are the longest
and the shortest diameters, respectively.
In vivo imaging was performed at 7, 14, 21, 28, and 35 days after fat pad injection
and at days 1, 5, 7, 10, 14, 21, and 28 after i.v. injection. Anesthetized animals (1–3%
isoflurane, Merial Italia S.p.A, Italy) were given the substrate D-Luciferin (Biosynth
AG, Switzerland) by intraperitoneal injection at 150mg/kg in PBS (Sigma). Imaging
times ranged from 15 s to 5min, depending on the tumor model and time point. The
light emitted from the bioluminescent tumors or metastasis was detected using a
cooled charge-coupled device camera mounted on a light-tight specimen box (IVIS
Lumina II Imaging System; Caliper Life Sciences, Alameda, CA). Regions of interest
from the displayed images were identified around the tumor sites or metastasis
regions, such as the lymph node and lungs, and quantified as total photon counts
(photon/s) using Living Image® software (Xenogen). For ex vivo imaging, 150mg/kg
of D-Luciferin was injected into the mice just before necropsy. The lungs were excised,
placed in a Petri plate and imaged.
Primary tumors were extracted and directly frozen in liquid nitrogen for molecular
analyses. Lymph nodes and lungs were excised, formalin-fixed and paraffin-
embedded for hematoxylin-eosin staining, Picro Sirius or Ki67, αSMA, and
CD31 staining. The antibodies used are listed in the Supplementary Table 3. For the
metastasis experiment, mice were treated with preconditioning media for 10 days
before fat pad tumor injection. The primary tumor was afterwards removed after
14 days of fat pad injection in anesthetized mice and the lymph nodes and lungs
metastases were monitored for 3 weeks.
Procedures involving animals and their care were in conformity with national (D.
L. 26/2014 and subsequent implementing circulars) and international (EU Directive
2010/63/EU for animal experiments) laws and policies, and the experimental protocol
(Authorization n. 1143/2015-PR) was approved by the Ethical Committee of the
University of Padua (CEASA) and by the Italian Ministry of Health.
LFS patients, tissues, and sample preparation. All skin biopsy samples were
explanted, established, and cultured by The Centre for Applied Genomics (TCAG)
at The Hospital for Sick Children, as described in the protocol below. Briefly, the
samples were stored at 4 °C and processed within 2 days, biopsies were dissociated
using collagenase, and then treated with Trypsin EDTA; the obtained cells were
cultured until the cell line could be expanded, frozen, and stored in liquid nitrogen
until required. The cell lines used were derived from 5 or fewer passages.
Analysis of p53 status. Genomic DNA was isolated from FFPE breast cancer
tissue samples using the QIAamp DNA FFPE Tissue Kit (Qiagen).
The TP53 mutational status was assessed by TaqMan mutation Detection Assay
(Life Technologies), based on Competitive Allele-Specific TaqMan PCR (CastPCR)
technology to detect the following TP53 mutations: (c.524G>A/p.R175H,
c.535C>T/p.H179Y c.742C>T/p.R248W, c.659A>/p.Y220C, c.818G>T/p.R273L,
c.488A>G/p.Y163C, c.711G>T/p.M273I, c.517G>T/p.V173L, c.818G>A/p.R273H,
c.743G>A/p.R248Q), according to the manufacturer’s instructions.
Immunohistochemistry analyses. Immunohistochemistry was carried out on
FFPE mouse and human tissue sections. Briefly, sections 2.5/3-micron-thick were
cut from paraffin blocks, dried, de-waxed, and rehydrated. The antigen unmasking
technique was performed using Target Retrieval Solutions pH 6 and pH 9 in a PT
Link Dako pre-treatment module at 98 °C for 30 min. Subsequently, the sections
were brought to room temperature and washed in PBS. After neutralization of the
endogenous peroxidase with 3% H2O2 and Fc blocking by a specific protein block
(Novocastra, UK), double-marker immunohistochemistry was carried out by
incubation overnight at 4 °C with a cocktail of two primary antibodies with dif-
ferent made (i.e., mouse and rabbit).
The mouse tissue samples were incubated with the following primary
antibodies: Ki67 (Abcam ab16667), αSMA (Abcam ab5694), and CD31 (Abcam
ab124432), and with the Dako envision HRP-labeled polymer anti-rabbit
secondary (ThermoScientific). Staining was revealed using DAB Quanto Kit
(ThermoScientific). The Picro Sirius Red staining was performed as indicated by
manufacturer (Picro Sirius Red Stain Kit ab150681). The slides were counterstained
with Harris hematoxylin (Novocastra), and images acquired with ×40 objective in
the DM4000B microscope (Leica) using the software Leica Application Suite 4.12.
Human tissue samples were incubated with the following primary antibodies:
mouse Monoclonal p53 (clone DO-7; 1:50 pH 6; Novocastra), rabbit Polyclonal
Sec24a (1:50 pH 6; Abcam), rabbit Polyclonal COL6A2 (1:100 pH 6; Invitrogen),
rabbit Polyclonal FREM2 (1:200 pH 6; Abcam). Staining was revealed using
MACH2 Double Stain detection kit (Biocare Medical), DAB (3,3′-
diaminobenzidine) and Vulcan Fast Red as substrate chromogens. The slides were
counterstained with Harris hematoxylin (Novocastra).
For double-marker immunofluorescence, sections were incubated with the
following primary antibodies: mouse Monoclonal p53 and mouse Monoclonal
Laminin beta-3 (clone CL3363; 1:200 pH 6; Invitrogen). The binding of the
primary antibodies to their respective antigenic substrates was revealed by Opal
Multiplex IHC kit, which allowed for combined immunostainings using antibodies
with a same made through tyramide signal amplification. After deparaffinization,
antigen retrieval was performed using microwave heating in pH 6 or pH 9 buffer
and the first primary antibody was incubated. Immunofluorescence labeling was
achieved by incubating with a specific secondary antibody followed by the addition
of one selected Opal fluorophore and microwave treatment in pH 6 buffer. The
same procedure was repeated for the second primary antibody using a different
Opal fluorophore and DAPI nuclear counterstain.
Human MiR30d probe hybridization (Hs-pre-MIR30D-1zz-st; Gene ID 407033;
RefSeq accession NR_029599.1; Cod. 720351; Advanced Cell Diagnostic) was
performed using BaseScope Detection kit (Advanced Cell Diagnostic) in
accordance with the manufacturer’s protocol91 adopting an extended 1-h
incubation in Amp 5 and 30-min incubation in Amp 6 buffers.
All the sections were analyzed under a Zeiss AXIOScope.A1 optical microscope
(Zeiss, Germany) and microphotographs were collected using a Zeiss Axiocam 503
Color digital camera using the Zen 2.0 imaging software.
For quantification analyses of Ki67 and αSMA staining in metastatic lung
samples from mice, positive cells were detected and counted. The Picro Sirius Red
Stain positive areas were quantified calculating the labeled area over a fixed
threshold normalized to total area by the ImageJ suite76. The CD31 staining was
analyzed evaluating the number of vessels and calculating the vessel area
normalized to total area by the Fiji ImageJ suite76. All the analyses were performed
in three different fields/mouse in at least 6 mice/condition.
In human breast cancer tissue section analisys, to reduce the presence of
stochastic noise for quantification analyses of images with high magnification
factor, we applied the methodology described in ref. 92 that maintains details of the
finest components. A further pre-processing step consists in the normalization of
images to have the same average and standard deviation of their RGB color values:
all images result comparable and do not require to be handled individually. The
final segmentation was obtained by applying the so-called “‡ trous” wavelet
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transform that retains the same resolution as the original photomicrograph93.
Quantitative in situ hybridization analysis for miR-30d in tumor foci was
performed by calculating the average percentage of positive signals in five non-
overlapping fields at high-power magnification (×40) using the Positive Pixel
Count v9 Leica Software Image Analysis.
Collection and processing of breast cancer gene expression data. Breast cancer
gene expression data have been obtained from a collection of 4640 samples from 27
major datasets comprising microarray data of breast tumors annotated with
pathological information and clinical outcome. All data were measured on Affy-
metrix arrays and have been downloaded from NCBI Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and EMBL-EBI ArrayExpress (http://
www.ebi.ac.uk/arrayexpress/). Prior to analysis, all datasets have been re-organized
as described in ref. 94; gene expression levels were normalized and quantified as
previously described95. The type and content of pathological and clinical annota-
tions have been standardized, among the various datasets, as described in ref. 96.
This resulted in a compendium (meta-data set) comprising 3661 unique samples
from 25 independent cohorts. Average signature expression has been calculated as
the standardized average expression of all signature genes in sample subgroups
(e.g., p53 status). The values shown in the bar graph are thus adimensional. All
gene expression analyses were performed in R (version 3.5.1).
Statistical analyses and reproducibility. All the experiments are representative of
at least three independent replicates. All graphs represent single data point mean ±
SEM. Statistical tests were performed using GraphPad Prism8. P values were
obtained using two-tailed Student’s unpaired parametric t-test. Blot and micro-
graphs are representative of three independent experiments, experiments for which
we showed representative images were performed with similar results at least three
independent times.
The commercial reagents, experimental models and software used in the present
study are listed in Supplementary Table 4.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting findings of this study are available within
the paper and its supplementary information files. Array data that support the findings of
this study have been deposited to GEO, accession number GSE133410. Lists of
differentially secreted proteins by mut-p53/miR-30d axis in MDA-MB-231 cells are
reported in Supplementary Data file 2. Public available data used in this were obtained
from: Ensembl (http://www.ensembl.org/index.html); UCSC (http://genome.ucsc.edu/
cgibin/ hgGateway); DAVID Bioinformatics Resources 6.8 (https://david.ncifcrf.gov/);
GSEA Gene Set Enrichment Analysis (https://www.gsea-msigdb.org/gsea/index.jsp);
TargetScan (www.targetscan.org); GOCC (http://geneontology.org/); SecretomeP 2.0
(http://www.cbs.dtu.dk/services/SecretomeP/); SignalIP (http://www.cbs.dtu.dk/services/
SignalP/); UniProt (https://www.uniprot.org/); Molecular Taxonomy of Breast Cancer
International Consortium, METABRIC97; The Cancer Genome Atlas (TCGA) breast
cancer dataset (https://www.cancer.gov/about-nci/organization/ccg/research/structural-
genomics/tcga). Source data are provided with this paper.
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